Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain

Brain

Volumn 138, Issue 6, 2015, Pages 1738-1755

  Maphis, Nicole ^a   Xu, Guixiang ^b   Kokiko Cochran, Olga N ^b   Jiang, Shanya ^a   Cardona, Astrid ^c   Ransohoff, Richard M ^d   Lamb, Bruce T ^b   Bhaskar, Kiran ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d BIOGEN   (United States)

Author keywords

Alzheimer's disease; Microglia; Neuroinflammation; Tau protein; Tauopathies

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TAU PROTEIN; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEIN AGGREGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; HIPPOCAMPAL CA1 REGION; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; TAUOPATHY; ANIMAL; BRAIN; COMPLICATION; DEFICIENCY; GENETICS; HIPPOCAMPUS; HUMAN; KNOCKOUT MOUSE; MEMORY DISORDER; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE; TAUOPATHIES;

ANIMALS; BRAIN; HIPPOCAMPUS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MEMORY DISORDERS; MICE; MICE, KNOCKOUT; MICROGLIA; PHOSPHORYLATION; PRIMARY CELL CULTURE; PROTEIN AGGREGATES; RECEPTORS, CHEMOKINE; TAU PROTEINS; TAUOPATHIES;

EID: 84938709394     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv081     Document Type: Article

References (74)

1. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 2005; 25: 5446-54.
2. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003; 86: 582-90.
3. Bhaskar K, Maphis N, Xu G, Varvel NH, Kokiko-Cochran ON, Weick JP, et al. Microglial derived tumor necrosis factor-alpha drives Alzheimer's disease-related neuronal cell cycle events. Neurobiol Dis 2014; 62: 273-85.
4. Bhaskar K, B.T. The role of Ab and tau oligomers in the pathogenesis of Alzheimer's disease. In: Rahimi FaB G, editor. Non-fibrillar amyloidogenic protein assemblies-common cytotoxins underlying degenerative diseases. New York: Springer Science + Business Media B.V. 2012, p. 135-88.
5. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68: 19-31.
6. Bellucci A, Bugiani O, Ghetti B, Spillantini MG. Presence of reactive microglia and neuroinflammatory mediators in a case of frontotemporal dementia with P301S mutation. Neurodegener Dis 2011; 8: 221-9.
7. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglialactivation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165: 1643-52.
8. Bergmann CC, Yao Q, Stohlman SA. Microglia exhibit clonal variability in eliciting cytotoxic T lymphocyte responses independent of class I expression. Cell Immunol 1999; 198: 44-53.
9. Burns K, Martinon F, Tschopp J. New insights into the mechanism of IL-1beta maturation. Curr Opin Immunol 2003; 15: 26-30.
10. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991; 1: 213-6.
11. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006; 5: 824-8.
12. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9: 917-24.
13. Capruso DX, Levin HS. Cognitive impairment following closed head injury. Neurol Clin 1992; 10: 879-93.
14. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011; 286: 32713-22.
15. Clark SR, McMahon CJ, Gueorguieva I, Rowland M, Scarth S, Georgiou R, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab 2008; 28: 387-94.
16. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70: 462-73.
17. Cui JG, Hill JM, Zhao Y, Lukiw WJ. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Neuroreport 2007; 18: 115-9.
18. Demetrius L. Aging in mouse and human systems: a comparative study. Ann N Y Acad Sci 2006; 1067: 66-82.
19. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008; 28: 1707-21.
20. Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, et al. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev 2008; 59: 155-63.
21. Dudal S, Krzywkowski P, Paquette J, Morissette C, Lacombe D, Tremblay P, et al. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging 2004; 25: 861-71.
22. Flex A, Giovannini S, Biscetti F, Liperoti R, Spalletta G, Straface G, et al. Effect of proinflammatory gene polymorphisms on the risk of Alzheimer's disease. Neurodegener Dis 2014; 13: 230-6.
23. Fowler A, Forsman L, Eriksson M, Wickstrom R. Tick-borne encephalitis carries a high risk of incomplete recovery in children. J Pediatrics 2013; 163: 555-60.
24. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284: 12845-52.
25. Gallagher M, Burwell R, Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris Water Maze. Behav Neurosci 1993; 107: 618-26.
26. Gebicke-Haerter PJ. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 2001; 54: 47-58.
27. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord 2006; 21: 89-93.
28. Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord 2004; 19: 1221-6.
29. Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, Laferla FM, Olschowka JA, et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 2013; 33: 5053-64.
30. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-27.
31. Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA 1990; 87: 5827-31.
32. Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 2005; 4: 247-56.
33. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-35.
34. Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E, Murakami T, et al. Accumulation of filamentous tau in the cerebral cortex of human tau R406W transgenic mice. Am J Pathol 2005; 166: 521-31.
35. Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 2001; 60: 647-57.
36. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-16.
37. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-14.
38. Kelleher I, Garwood C, Hanger DP, Anderton BH, Noble W. Kinase activities increase during the development of tauopathy in htau mice. J Neurochem 2007; 103: 2256-67.
39. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 8843-53.
40. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 2011; 187: 6539-49.
41. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflam 2012; 9: 151.
42. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-9.
43. Lambourne SL, Sellers LA, Bush TG, Choudhury SK, Emson PC, Suh YH, et al. Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. Mol Cell Biol 2005; 25: 278-93.
44. Lamkanfi M, Dixit VM. The inflammasomes. PLoS Pathog 2009; 5: e1000510.
45. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
46. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-59.
47. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and onsynaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 2003; 23: 1605-11.
48. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PloS One 2012; 7: e31302.
49. Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 2004; 29: 1287-97.
50. Maei HR, Zaslavsky K, Teixeira CM, Frankland PW. What is the most sensitive measure of Water Maze probe test performance? Front Integr Neurosci 2009; 3: 4.
51. Maggi L, Scianni M, Branchi I, D'Andrea I, Lauro C, Limatola C. CX(3)CR1 deficiency alters hippocampal-dependent plasticity phenomena blunting the effects of enriched environment. Front Cell Neurosci 2011; 5: 22.
52. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22: 799-809.
53. McGeerPL,McGeerEG.NSAIDsandAlzheimerdisease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-47.
54. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
55. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136(Pt 1): 43-64.
56. Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron 2011; 70: 410-26.
57. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47-60.
58. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-41.
59. Payao SL, Goncalves GM, de Labio RW, Horiguchi L, Mizumoto I, Rasmussen LT, et al. Association of interleukin 1beta polymorphisms and haplotypes with Alzheimer's disease. J Neuroimmunol 2012; 247: 59-62.
60. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature 2010; 468: 253-62.
61. Reaux-Le Goazigo A, Van Steenwinckel J, Rostene W, Melik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog Neurobiol 2013; 104: 67-92.
62. Rogers JT, Morganti JM, Bachstetter AD, Hudson CE, Peters MM, Grimmig BA, et al. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci 2011; 31: 16241-50.
63. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 2012; 287: 3842-9.
64. Sato K, Hamanoue M, Takamatsu K. Inhibitors of p38 mitogenactivated protein kinase enhance proliferation of mouse neural stem cells. J Neurosci Res 2008; 86: 2179-89.
65. Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003; 44: 183-9.
66. Sasaki A, Kawarabayashi T, Murakami T, Matsubara E, Ikeda M, Hagiwara H, et al. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L. Brain Res 2008; 1214: 159-68.
67. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001; 39: 341-8.
68. Sheridan GK, Murphy KJ. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol 2013; 3: 130181.
69. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-15.
70. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53: 337-51.
71. Yuan H, Xia Q, Ge P, Wu S. Genetic polymorphism of interleukin 1beta-511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis. Mol Biol Reports 2013; 40: 1827-34.
72. Zhen X, Uryu K, Cai G, Johnson GP, Friedman E. Age-associated impairment in brain MAPK signal pathways and the effect of caloric restriction in Fischer 344 rats. J Gerontol A Biol Sci Med Sci 1999; 54: B539-48.
73. Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, et al. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflamm 2012; 9: 47.
74. Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M. Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy. J Neuroimmunol 2009; 209: 16-25.